A randomized, double-blind, placebo managed, stage III medical trial evaluated the efficacy and safety profile of adalimumab as being a monotherapy in clients with RA who had unsuccessful to respond to csDMARDs [191]. The effects confirmed equally statistically considerable enhancement within the disorder activity and a very good safety profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/